A Phase 3 interventional study of ARIMIDEX (anastrazole) and NOLVADEX (tamoxifen) in Breast Cancer, sponsored by AstraZeneca. Completed at 79 sites in 10 countries. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2010-02-03.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.
Among the 111 studies testing anastrozole in Breast Neoplasms, this one is the 26th largest by enrollment of the 109 interventional ones that give a count, is one of 2 that started in 2000, is one of 38 in phase 3, and was the 9th registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–75 · Women only
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–99
By country, each count listing its studies:
Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →
Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.
This study: 60 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, anastrozole is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 57 · Phase 3 38 · Phase 4 7
First in 1996; this study’s year is marked. 2 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Median enrollment 148 across the 109 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 111 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 32nd largest by enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2000, is one of 46 in phase 3, and was the 7th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
4 of the studies testing anastrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT03304080Icahn School of Medicine at Mount SinaiAnastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 111 studies testing anastrozole in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Objective tumour response
Time frame: Assessed at 3 months
Pathological response
Time frame: Assessed at 3 months
Extent of breast surgery
Time frame: Assessed at 3 months
Extent of axillary down-staging
Time frame: Assessed at 3 months
Clinical ultrasound response versus clinical caliper response
Time frame: Assessed at 3 months
Safety
Time frame: Assessed up to 5 years + 30 days
Complications due to surgery
Time frame: Assessed up to 30 days post-surgery
Health economics outcomes
Time frame: Assessed up to 30 days post-surgery
Quality of Life assessments
Time frame: Assessed at 3 months
Effect of ethnicity with respect to baseline patient and tumour characteristics, safety and objective tumour response rate
Time frame: Assessed up to 5 years + 30 days
Recurrence-free survival and survival
Time frame: Assessed up to 5 years
The record gives a start of Aug 2000, a primary completion of Jan 2003 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anastrozole · Tamoxifen